MTOR and ovarian carcinoma: Pathway analysis showed that the TP53 signaling pathway (mutation rate 80%), the DNA‐damage response signaling pathway (mutation rate 60%), the mTOR signaling pathway (mutation rate 60%), and the RTK signaling pathway (mutation rate 20%) were mutated in drug‐resistant recurrent ovarian cancer.